PTC Therapeutics, Inc. Current Part of Debt

Current Part of Debt of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending June 29, 2021 was $54 Million (a 28.57% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt increased by 86.21%
  • Annual Current Part of Debt for 2020 was $9 Million (a -64.0% decrease from previous year)
  • Annual Current Part of Debt for 2019 was $25 Million (a 108.33% increase from previous year)
  • Annual Current Part of Debt for 2018 was $12 Million (a 24389.8% increase from previous year)
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of PTC Therapeutics, Inc.

Most recent Current Part of Debtof PTCT including historical data for past 10 years.

Interactive Chart of Current Part of Debt of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $54.0 $42.0
2020 $9.0 $29.0 $27.0 $20.0 $9.0
2019 $20.0 $20.0 $20.0 $16.67 $25.0
2018 $11.67 $6.67 $1.67 $12.0
2016 $0.26
2014 $0.01
2013 $0.05 $0.08 $2.75 $3.82 $0.05
2012 $4.44 $4.44
2011 $7.13 $7.14

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.